Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs

Experimental Neurology

Volumn 255, Issue , 2014, Pages 96-102

  Desaphy, Jean François ^a   Carbonara, Roberta ^a   Costanza, Teresa ^a   Conte Camerino, Diana ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Mexiletine; Non dystrophic myotonia; Over excitability; Patch clamp; Rat model; Sodium channel blockers

Indexed keywords

CARBAMAZEPINE; FLECAINIDE; LUBELUZOLE; MEXILETINE; ORPHENADRINE; PROPAFENONE; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMYOTONIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; MYOTONIA; NONHUMAN; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RIGHTING REFLEX; SKELETAL MUSCLE; SODIUM CURRENT; STEADY STATE; VOLTAGE CLAMP TECHNIQUE;

MEXILETINE; NON-DYSTROPHIC MYOTONIA; OVER-EXCITABILITY; PATCH-CLAMP; RAT MODEL; SODIUM CHANNEL BLOCKERS;

ANIMALS; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; FLECAINIDE; HEK293 CELLS; HUMANS; MEXILETINE; MUSCLE, SKELETAL; MYOTONIA CONGENITA; ORPHENADRINE; PIPERIDINES; PROPAFENONE; RATS; RATS, WISTAR; RILUZOLE; SODIUM CHANNEL BLOCKERS; THIAZOLES;

EID: 84896451444     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.02.023     Document Type: Article

References (36)

1. Adrian R.H., Bryant S.H. On the repetitive discharge in myotonic muscle. J. Physiol. 1974, 240:505-515.
2. Alfonsi E., Merlo I.M., Tonini M., Ravaglia S., Brugnoni R., Gozzini A., Moglia A. Efficacy of propafenone in paramyotonia congenita. Neurology 2007, 68:1080-1081.
3. Bruno C., Carocci A., Catalano A., Cavalluzzi M.M., Corbo F., Franchini C., Lentini G., Tortorella V. Facile, alternative route to lubeluzole, its enantiomer, and the racemate. Chirality 2006, 18:227-231.
4. Burnett D.M., Gal J., Zahniser N.R., Nies A.S. Propafenone interacts stereoselectively with beta 1- and beta 2-adrenergic receptors. J. Cardiovasc. Pharmacol. 1988, 12(5):615-619.
5. Caietta E., Milh M., Sternberg D., Lépine A., Boulay C., McGonigal A., Chabrol B. Diagnosis and outcome of SCN4A-related severe neonatal episodic laryngospasm (SNEL): 2 new cases. Pediatrics 2013, 132(3):e784-e787.
6. Cannon S.C. Voltage-gated ion channelopathies of the nervous system. Clin. Neurosci. Res. 2001, 1:104-117.
7. Catalano A., Carocci A., Defrenza I., Muraglia M., Carrieri A., Van Bambeke F., Rosato A., Corbi F., Franchini C. 2-Aminobenzothiazole derivatives: search for new antifungal agents. Eur. J. Med. Chem. 2013, 64:357-364.
8. - in rat EDL muscle in vitro and in vivo: physiology and pathophysiology. J. Gen. Physiol. 2013, 141:179-192.
9. Conte Camerino D., Tricarico D., Desaphy J.-F. Ion channel pharmacology. Neurotherapeutics 2007, 4:184-198.
10. Desaphy J.-F., Conte Camerino D., Tortorella V., De Luca A. Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia. Neuromuscul. Disord. 1999, 9:182-189.
11. Desaphy J.-F., De Luca A., Tortorella P., De Vito D., George A.L., Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 2001, 57:1849-1857.
12. Desaphy J.-F., Pierno S., De Luca A., Didonna M.P., Conte Camerino D. Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders. Mol. Pharmacol. 2003, 63:659-670.
13. Desaphy J.-F., De Luca A., Didonna M.P., George A.L., Conte Camerino D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J. Physiol. 2004, 554:321-334.
14. Desaphy J.-F., Dipalma A., De Bellis M., Costanza T., Gaudioso C., Delmas P., George A.L., Conte Camerino D. Involvement of voltage-gated sodium channels blockade in the analgesic action of orphenadrine. Pain 2009, 142(3):225-235.
15. Desaphy J.-F., Dipalma A., Costanza T., Carbonara R., Dinardo M.M., Catalano A., Carocci A., Lentini G., Franchini C., Conte camerino D. Molecular insights into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine. Front. Pharmacol. 2012, 3:17.
16. Desaphy J.-F., Modoni A., Lomonaco M., Conte Camerino D. Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. Eur. J. Clin. Pharmacol. 2013, 69:1037-1039.
17. Desaphy J.-F., Costanza T., Carbonara R., Conte Camerino D. In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia. Neuropharmacology 2013, 65:21-27.
18. Desaphy J.-F., Carbonara R., Costanza T., Lentini G., Cavalluzzi M.M., Bruno C., Franchini C., Conte Camerino D. Molecular dissection of lubeluzole use-dependent block of voltage-gated sodium channels discloses new therapeutic potentials. Mol. Pharmacol. 2013, 83(2):406-415.
19. + transport in rat soleus muscle. Nature 1976, 281:580-581.
20. 4, FFA, and glycerol in human forearms. J. Appl. Physiol. 1995, 78:172-178.
21. Gandolfo C., Sandercock P., Conti M. Lubeluzole for acute ischaemic stroke. Cochrane Database Syst. Rev. 2002, 1:CD001924.
22. Hoppe K., Lehmann-Horn F., Chaiklieng S., Jurkat-Rott K., Adolph O., Klingler W. In vitro muscle contracture investigations on the malignant hyperthermia like episodes in myotonia congenita. Acta Anaesthesiol. Scand. 2013, 57:1017-1023.
23. Lion-Francois L., Mignot C., Vicart S., Manel V., Sternberg D., Landrieu P., Lesca G., Broussolle E., Billette de Villemeur T., Napuri S., des Portes V., Fontaine B. Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder. Neurology 2010, 75(7):641-645.
24. Logigian E.L., Martens W.B., Moxley R.T., McDermott M.P., Dilek N., Wiegner A.W., Pearson A.T., Barbieri C.A., Annis C.L., Thornton C.A., Moxley R.T. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010, 74:1441-1448.
25. Lyons M.J., Duron R., Molinero I., Sangiuolo F., Holden K.R. Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita. Pediatr. Neurol. 2010, 42:365-368.
26. Matthews E., Fialho D., Tan S.V., Venance S.L., Cannon S.C., Sternberg D., Fontaine B., Amato A.A., Barohn R.J., Griggs R.C., Hanna M.G., CINCH investigators The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 2010, 133:9-22.
27. McLean M.J., Macdonald R.L. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 1986, 238:727-738.
28. Rayan D.R., Hanna M.G. Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. Curr. Opin. Neurol. 2010, 23:466-476.
29. Rosenfeld J., Sloan-Brown K., George A.L. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann. Neurol. 1997, 42:811-814.
30. Savitha M.R., Krishnamurthy B., Hyderi A., Farhan-Ul-Haque, Ramachandra N.B. Myotonia congenita - a successful response to carbamazepine. Indian J. Pediatr. 2006, 73:431-433.
31. Sechi G.P., Traccis S., Durelli L., Monaco F., Mutani R. Carbamazepine versus diphenylhydantoin in the treatment of myotonia. Eur. Neurol. 1983, 22(2):113-118.
32. Statland J.M., Bundy B.N., Wang Y., Rayan D.R., Trivedi J.R., Sansone V.A., Salajeqheh M.K., Venance S.L., Ciafaloni E., Matthews E., Meola G., Herbelin L., Griggs R.C., Barohn R.J., Hanna M.G. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 2012, 308(13):1357-1365. Consortium for Clinical Investigation of Neurologic Channelopathies.
33. Trivedi J.R., Bundy B., Statland J., Salajeqheh M., Rayan D.R., Venance S.L., Wang Y., Fialho D., Matthews E., Cleland J., Gorham N., Herbelin L., Cannon S., Amato A., Griggs R.C., Hanna M.G., Barohn R.J. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain 2013, 136:2189-2200. CINCH consortium.
34. Trivedi J.R., Cannon S.C., Griggs R.C. Nondystrophic myotonia: challenges and future directions. Exp. Neurol. 2013, (Dec 18, Epub ahead of print). 10.1016/j.expneurol.2013.12.005.
35. + channels. J. Physiol. 2004, 554:621-633.
36. Yoshimura R., Yanagihara N., Terao T., Minami K., Toyohira Y., Ueno S., Uezono Y., Abe K., Izumi F. An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultures bovine adrenal medullary cells. Psychopharmacology 1998, 135:368-373.